Orgenesis Inc. (ORGS)
Orgenesis Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Germantown, MD, US. The stock last traded at $0.35, down 0.03% on the session, giving a market capitalisation of $3.4M. On trailing twelve-month figures it carries a trailing P/E of -0.18, a net margin of -10445.5%. Its beta of 3.20 implies it has historically moved more than the broad market.
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
Orgenesis Inc. is most often compared with the following Healthcare names: